![sato goban sato goban](https://i.pinimg.com/474x/2a/12/9c/2a129c62c8c22e99ea958ee32ceb41a8.jpg)
This leads to rapid cell swelling, blebbing, and rupture, which leads to immunogenic cell death (ICD). APCs bind to target molecules on the cell surface, and when exposed to NIR light, cause disruption of the cell membrane due to the ligand release reaction and dye aggregation. Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed and promising therapy that specifically destroys target cells by irradiating antibody-photo-absorber conjugates (APCs) with NIR light. In this review, NIR-PIT is introduced, and its potential therapeutic applications for thoracic cancers are described. Additionally, techniques are being developed to further develop NIR-PIT for clinical practice.
![sato goban sato goban](https://i.pinimg.com/originals/a5/4c/f3/a54cf362512273989df82dcccc2f9e95.jpg)
In combination with these various specific targets, NIR-PIT is expected to be an ideal therapeutic approach for thoracic tumors.
![sato goban sato goban](https://i.pinimg.com/474x/63/ce/e3/63cee3a09885c2884b0df097de9d7533.jpg)
In recent years, it has become clear that various specific and promising targets are highly expressed in thoracic tumors. NIR-PIT can apply to any target by changing to different antigens. Recently, near-infrared photoimmunotherapy (NIR-PIT), which is a completely different concept from conventional PDT, has been developed and approved in Japan for the treatment of recurrent and previously treated head and neck cancer because of its specificity and effectiveness. Light therapy for thoracic tumors has long been used as an alternative conventional light therapy also called photodynamic therapy (PDT) has been used mainly for early-stage lung cancer.